Hyperinsulinaemic hypoglycaemia.
Hyperinsulinaemic hypoglycaemia (HH) occurs as a consequence of unregulated insulin secretion from pancreatic beta cells. In the newborn period it is the most common cause of severe and persistent hypoglycaemia. As HH is a major risk factor for brain injury and subsequent neurodevelopment handicap, the identification, rapid diagnosis and prompt management of patients with HH is essential if brain damage is to be avoided. Advances in molecular genetics, radiological imaging techniques (such as fluorine-18 L-3, 4-dihydroxyphenylalanine positron emission tomography ((18F)DOPA-PET) scanning) and laparoscopic surgery have completely changed the clinical approach to infants with the severe congenital forms of HH. This review gives an outline of the clinical presentation, the diagnostic cascade, the underlying molecular mechanisms and the management of HH with a particular focus on congenital forms of hyperinsulinism.
Kapoor
R R
RR
Institute of Child Health, University College London, London, UK.
Flanagan
S E
SE
James
C
C
Shield
J
J
Ellard
S
S
Hussain
K
K
D044903:Congenital Hyperinsulinism / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D004252:DNA Mutational Analysis; D003981:Diazoxide / Q000627:therapeutic use; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000378:metabolism; D010180:Pancreatectomy / Q000379:methods; D014665:Vasodilator Agents / Q000627:therapeutic use
D007328:Insulin; D014665:Vasodilator Agents; D003981:Diazoxide